优化人用狂犬病疫苗供应链:一项模型研究
该模型研究基于坦桑尼亚和肯尼亚各五年犬咬伤患者数据,拟合负二项分布模拟暴露后预防疫苗需求,比较WHO推荐的肌内与皮内接种方案的疫苗使用和缺货情况,并评估库存管理策略。结果显示皮内接种可减少超过55%的疫苗瓶使用并降低缺货风险,分散暴露后预防至更多机构改善可及性但增加疫苗瓶使用。
要点
- 皮内接种较肌内接种减少超过55%的疫苗瓶使用并降低缺货风险,在低通量机构中风险缓解最明显。
- 犬咬伤患者需求波动大,6%的月份超过月均就诊量的3倍,低发病率环境中波动最极端。
- 分散暴露后预防至更多机构改善可及性,但减少疫苗瓶共享机会从而增加疫苗瓶使用。
核心结论
- 皮内接种减少疫苗瓶使用和缺货,即使在低通量环境中亦然;根据患者通量调整预警阈值和补货量可简化狂犬病疫苗整合入基本免疫供应链,但需考虑后勤权衡。
研究设计与样本
- 对坦桑尼亚(6646例患者,20个地区)和肯尼亚(199112例患者,47个县)各五年犬咬伤患者数据拟合负二项分布,参数化模拟WHO推荐的肌内和皮内暴露后预防方案下的疫苗需求。
主要发现
- 犬咬伤患者发病率变化剧烈,需求激增远超月平均值,6%的月份超过月均就诊量的3倍,低发病率环境中波动最极端。
- 皮内接种减少超过55%的疫苗瓶使用并降低缺货风险。
- 皮内接种下,高通量环境中疫苗瓶节省最大,低通量环境中风险缓解最大化。
- 分散暴露后预防至更多机构改善可及性,但减少疫苗瓶共享机会从而增加疫苗瓶使用。
- 根据患者通量确定了韧性供应链策略,可适应需求变化。
关键数值与推荐
- 皮内接种较肌内接种减少超过55%的疫苗瓶使用。
- 6%的月份犬咬伤患者就诊量超过月均值的3倍。
临床怎么用
- 作者认为皮内接种可减少疫苗瓶使用和缺货,即使在低通量环境中亦然。
- 作者认为根据患者通量调整预警阈值和补货量可简化狂犬病疫苗整合入基本免疫供应链,改善可及性并预防不必要的死亡,但需考虑后勤权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rabies causes thousands of deaths annually in low- and middle-income countries. Despite effective vaccines for post-exposure prophylaxis (PEP), their expense, coupled with supply chain failures, leads to stockouts and preventable deaths. Investment by Gavi, the Vaccine Alliance, aims to improve access to post-exposure vaccines. We evaluate PEP demand in Tanzania and Kenya and examine stock management strategies for improving supply chains in Gavi-eligible countries. METHODS: We fitted negative binomial distributions to five years of bite patient data from Tanzania (6646 patients, 20 districts) and Kenya (199,112 patients, 47 counties) to parameterise simulations of post-exposure vaccine demand under WHO-recommended intramuscular (IM) and intradermal (ID) regimens. We compared simulated vaccine use, stockouts, and the impact of stock management strategies across the observed range in demand. RESULTS: Bite patient incidence varied dramatically; demand surges far exceeded monthly averages (in 6 % of months exceeding 3× average monthly bite patient presentations) and were most extreme in low-incidence settings. ID vaccination reduces vial use by >55 % and reduces stockout risk. Under ID vaccination vial savings are greatest in high-throughput settings, whilst risk mitigation is maximised in low-throughput settings. Decentralizing PEP to more facilities improves access, though reduces vial-sharing opportunities and so increases vial use. Resilient supply chain strategies were identified according to patient throughput, allowing for adaptation to changing demand. CONCLUSIONS: ID vaccination reduces vial use and stockouts, even in low-throughput settings. Tailoring stock management-through adjusted alert thresholds and restocking volumes-can simplify the integration of rabies vaccines into essential immunisation supply chains, improving their availability and preventing unnecessary deaths. However, logistical trade-offs must also be considered.
引用
- Luka MM, Ferguson EA, Rees E, et al. Optimising human rabies vaccine supply chains: A modelling study. Vaccine. 2025. PMID: 40274463. doi:10.1016/j.vaccine.2025.127108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。